[English]  [Pусский]  [中文]  
 
ctt-journal > Pavlova O. et al. (Abstract)

Pavlova O. et al. (Abstract)

Cellular Therapy and Transplantation (CTT), Vol. 3, No. 12
doi: 10.3205/ctt-2011-No12-abstract10

© The Authors. This abstract is provided under the following license: Creative Commons Attribution 3.0 Unported

Abstract accepted for "5th Raisa Gorbacheva Memorial Meeting Hematopoietic Stem Cell Transplantation in Children and Adults", Saint Petersburg, Russia, September 18–20, 2011

Preliminary Program

Contribute a comment

 

Efficacy of high dose chemotherapy and autologous stem cell transplantation (auto-HSCT) in primary mediastinal large В-cell lymphoma (PMLBCL)

Olga A. Pavlova, Maria A. Vernyuk, Vera A. Zerebtsova, Natalia G. Tyurina

P. A. Hertcen Moscow Scientific Research Oncology Center, Moscow, Russia

Correspondence: Natalia G. Tyurina, P. A. Hertcen Moscow Scientific Research Oncology Center, Second Botkinskii proezd, 2, Moscow, 125284, Russia, Е-mail: tng-mnioi@spam is badmail.ru

Abstract

Here we present outcomes of first-line chemotherapy and auto-HSCT in patients with PMLBCL. Twenty-two patients with PMLBCL (6 m. and 16 f.) admitted to Hertcen Oncology Center from 2005 to 2011 were included in this study. The median age was 33 (range 23–64) years. Their PMLBCL diagnosis was confirmed by immunomorphological study. Samples were obtained by mediastinotomy (n=8), percutaneous needle biopsy (n=8), thoracotomy (n=4) or neck/supraclavicular lymph node biopsy (n=2). At the time of diagnosis 19 patients had stage II-E disease, and 3 patients had stage III-E disease according to the Ann Arbor staging system. Bone marrow involvement was not observed. Local infiltration of adjacent tissues and organs was defined in the majority of patients (58 % — lungs, 74 % — pericardium, 79 % — pleura, 22 % — thoracal wall). Seventy-six percent of patients presented with hydrothorax and/or hydrocardia. Superior vena cava syndrome was observed in 69 % of patients, and thrombosis in 66 %. Fifty-seven percent of patients had an elevated LDH level. Rituximab containing first line chemotherapy was performed in 13 patients (R-CHOP: 1, R-CHOEP: 1, R-MACOP-B: 11) and 9 patients received a regimen without rituximab (MACOP-B). Patients with good remission received radiotherapy on the residual tumor (n=8). Patients with adverse prognostic factors or partial remission received auto-HSCT (n=10). For patients who received rituximab at the induction stage, auto-HSCT was required in 38% (5 of 13) of cases, while 56 % of patients who did not receive rituximab required auto-HSCT (5 of 9 cases). Currently 20 patients are in first full/partial remission, and the average time of follow-up is 29 months (range, 2–57). Two patients died due to disease progression after auto-HSCT and complications of treatment after radiotherapy.

Keywords: primary mediastinal large B-cell lymphoma, MACOP-B, rituximab, radiation therapy, autologous stem cell transplantation